Harren Jhoti

Harren Jhoti
FRS FMedSci FRSB FRSC
Born 1962 (age 55–56)[1]
India
Alma mater
Known for Astex
Awards Chemistry World Entrepreneur of the Year (2007)[3]
Scientific career
Fields Drug discovery
Structural biology
Institutions Astex
GlaxoWellcome
University of Oxford
Thesis X-ray structural studies on transferrins (1989)
Influences Tom Blundell
David Ian Stuart[3]
Website astx.com/portfolio-item/harren-jhoti/

Harren Jhoti (born 1962)[1] FRS FMedSci FRSB FRSC is a structural biologist whose main interest has been rational drug design.[4] He is President & Chief Executive Officer (CEO) of Astex Pharmaceuticals in Cambridge, a biotechnology company he co-founded with Tom Blundell and Chris Abell in 1999.[5][4] He pioneered the development of fragment-based lead discovery, an approach now widely used in industry and academia to discover new medicines.[6][7]

Astex's first drug, called Kisqali, which originated from a collaboration with Novartis, was approved in 2017 for patients with metastatic breast cancer in the United States and European Union.[4] In 2013 Astex was acquired by Otsuka Pharmaceutical for $886m, and operates as a wholly owned subsidiary of the Japanese company. Prior to Astex, Jhoti was Head of Structural Biology at GlaxoWellcome (now GSK).[4]

References

  1. 1 2 3 Anon (2016). Jhoti, Dr Harren. ukwhoswho.com. Who's Who (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. doi:10.1093/ww/9780199540884.013.286522. (subscription required)
  2. ↑ Jhoti, Harren (1989). X-ray structural studies on transferrins. London.ac.uk (PhD thesis). University of London. OCLC 940322045. Copac 29529053.
  3. 1 2 Houlton, Sarah (2008). "Harren Jhoti profile" (PDF). Rsc.org. Chemistry World.
  4. 1 2 3 4 Anon (2018). "Dr Harren Jhoti FRS". Royalsociety.org. London: Royal Society. Archived from the original on 2018-05-14. One or more of the preceding sentences incorporates text from the royalsociety.org website where:
    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"{title}". Archived from the original on 2016-11-11. Retrieved 2018-05-23.
  5. ↑ "Harren Jhoti – Astex". Astx.com. Retrieved 23 May 2018.
  6. ↑ "Dr Harren Jhoti - The Academy of Medical Sciences". Acmedsci.ac.uk. Retrieved 23 May 2018.
  7. ↑ Jhoti, Harren; Williams, Glyn; Rees, David C.; Murray, Christopher W. (2013). "The 'rule of three' for fragment-based drug discovery: where are we now?". Nature Reviews Drug Discovery. 12 (8): 644–644. doi:10.1038/nrd3926-c1. ISSN 1474-1776. PMID 23845999.

 This article incorporates text available under the CC BY 4.0 license.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.